Regina Hodits

Regina is a Managing Partner at Wellington Partners and represents the Wellington funds on the Boards of Ayoxxa, Carisma, Endostim, GTX Medical, Themis and TRiCares. She was a founding investor in Rigontec (acquired by MSD), Sapiens (acquired by Medtronic), Middle Peak Medical (acquired by Symetis / Boston Scientific) and an external director at GlaxoSmithKline's Respiratory TA Board. Since joining the industry in 2000, she has become an influential investor in the European VC industry, focusing on early-stage and growth deals

in Life Sciences. She currently serves as the Spokesperson for the Board of the German PE and Venture Capital Association (BVK).

Further stations of her career were McKinsey, Atlas Venture and Apax Partners, for which she served on several boards including Bicycle Therapeutics, F-star, Jenavalve, U3 Pharma, Nitec Pharma, Egalet and Novamed. Regina studied chemical engineering in Vienna and holds a Ph.D. in biochemistry.